XNAS · Healthcare · Biotechnology
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -5.37 | -7.30 | -35.94% | $0 | ❌ Miss | -1.27% | +0.80% | — |
| 2025-11-17 | Q3 2025 | -6.63 | -5.76 | +13.12% | $0 | ✅ Beat | — | — | — |
| 2024-11-15 |
| Q3 2024 |
| -5.00 |
| -12.50 |
| -150.00% |
| $0 |
| ❌ Miss |
| +14.18% |
| +18.36% |
| -2.00% |
| 2024-08-14 | Q2 2024 | — | -336.00 | — | $0 | — | +1.81% | +19.86% | +7.00% |
| 2024-05-15 | Q1 2024 | — | -1025.00 | — | $0 | — | +12.68% | +3.66% | -72.04% |
| 2024-04-01 | Q4 2023 | — | -2375.00 | — | $0 | — | -14.54% | -37.74% | -39.41% |
| 2023-11-14 | Q3 2023 | — | -2700.00 | — | $0 | — | +14.97% | +25.15% | +5.39% |
| 2023-08-14 | Q2 2023 | — | -2600.00 | — | $0 | — | -3.39% | -31.07% | -14.69% |
Showing last 8 quarters.